Corbett, Max and Bogers, Willy M. and Heeney, Jonathan L. and Gerber, Stefan and Genin, Christian and Didierlaurent, Arnaud and Oostermeijer, Herman and Dubbes, Rob and Braskamp, Gerco and Lerondel, Stephanie and Gomez, Carmen E. and Esteban, Mariano and Wagner, Ralf and Kondova, Ivanella and Mooij, Petra and Balla-Jhagjhoorsingh, Sunita and Beenhakker, Niels and Koopman, Gerrit and van der Burg, Sjoerd and Kraehenbuhl, Jean-Pierre and Le Pape, Alain (2008) Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105 (6). pp. 2046-2051. ISSN 0027-8424,
Full text not available from this repository. (Request a copy)Abstract
Each year, approximately five million people die worldwide from putatively vaccine-preventable mucosally transmitted diseases. With respect to mass vaccination campaigns, one strategy to cope with this formidable challenge is aerosol vaccine delivery, which offers potential safety, logistical, and cost-saving advantages over traditional vaccination routes. Additionally, aerosol vaccination may elicit pivotal mucosal immune responses that could contain or eliminate mucosally transmitted pathogens in a preventative or therapeutic vaccine context. In this current preclinical non-human primate investigation, we demonstrate the feasibility of aerosol vaccination with the recombinant poxvirus-based vaccine vectors NYVAC and MVA. Real-time in vivo scintigraphy experiments with radiolabeled, aerosol-administered NYVAC-C (Clade C, HIV-1 vaccine) and MVA-HPV vaccines revealed consistent mucosal delivery to the respiratory tract. Furthermore, aerosol delivery of the vaccines was safe, inducing no vaccine-associated pathology, in particular in the brain and lungs, and was immunogenic. Administration of a DNA-C/NYVAC-C prime/boost regime resulted in both systemic and anal-genital HIV-specific immune responses that were still detectable 5 months after immunization. Thus, aerosol vaccination with NYVAC and MVA vectored vaccines constitutes a tool for large-scale vaccine efforts against mucosally transmitted pathogens.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | T-CELL RESPONSES; PREEXISTING POXVIRUS IMMUNITY; VIRUS ANKARA; NONHUMAN-PRIMATES; CYSTIC-FIBROSIS; MEASLES-VACCINE; CLADE-C; DELIVERY; ANTIGEN; DEPOSITION; MVA HPV; non-human primate; NYVAC HIV; preclinical study; aerosol vaccine assessment |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 09 Nov 2020 11:45 |
| Last Modified: | 09 Nov 2020 11:45 |
| URI: | https://pred.uni-regensburg.de/id/eprint/31379 |
Actions (login required)
 |
View Item |
